<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24569856</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7209</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Angiogenesis</Title>
                <ISOAbbreviation>Angiogenesis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>661-73</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10456-014-9422-9</ELocationID>
            <Abstract>
                <AbstractText>An alternative or follow-up adjunct to conventional maximum tolerated dose (MTD) chemotherapy now in advanced phase III clinical trial assessment is metronomic chemotherapy--the close regular administration of low doses of drug with no prolonged breaks. A number of preclinical studies have shown metronomic chemotherapy can cause long term survival of mice with advanced cancer, including metastatic disease, in the absence of overt toxicity, especially when combined with targeted antiangiogenic drugs. However, similar to MTD chemotherapy acquired resistance eventually develops, the basis of which is unknown. Using a preclinical model of advanced human ovarian (SKOV-3-13) cancer in SCID mice, we show that acquired resistance can develop after terminating prolonged (over 3 months) successful therapy utilizing daily oral metronomic topotecan plus pazopanib, an oral antiangiogenic tyrosine kinase inhibitor (TKI). Two resistant sublines were isolated from a single mouse, one from a solid tumor (called KH092-7SD, referred to as 7SD) and another from ascites tumor cells (called KH092-7AS, referred to as 7AS). Using these sublines we show acquired resistance to the combination treatment is due to tumor cell alterations that confer relative refractoriness to topotecan. The resistant phenotype is heritable, associated with reduced cellular uptake of topotecan and could not be reversed by switching to MTD topotecan or to another topoisomerase-1 inhibitor, CPT-11, given either in a metronomic or MTD manner nor switching to another antiangiogenic drug, e.g. the anti-VEGFR-2 antibody, DC101, or another TKI, sunitinib. Thus, in this case cross resistance seems to exist between MTD and metronomic topotecan, the basis of which is unknown. However, gene expression profiling revealed several potential genes that are stably upregulated in the resistant lines, that previously have been implicated in resistance to various chemotherapy drugs, and which, therefore, may contribute to the drug resistant phenotype.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cruz-Mu√±oz</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biological Sciences Platform, S-217, Sunnybrook Research Institute, 2075 Bayview Ave., Toronto, ON, M4N 3M5, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Desidero</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Man</LastName>
                    <ForeName>Shan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaramillo</LastName>
                    <ForeName>Maria Luz</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hashimoto</LastName>
                    <ForeName>Kae</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banville</LastName>
                    <ForeName>Myriam</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connor-McCourt</LastName>
                    <ForeName>Maureen D</ForeName>
                    <Initials>MD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kerbel</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA041233</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA-41233</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>02</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Angiogenesis</MedlineTA>
            <NlmUniqueID>9814575</NlmUniqueID>
            <ISSNLinking>0969-6970</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7673326042</RegistryNumber>
                <NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7M7YKX2N15</RegistryNumber>
                <NameOfSubstance UI="D019772">Topotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7RN5DR86CK</RegistryNumber>
                <NameOfSubstance UI="C516667">pazopanib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XT3Z54Z28A</RegistryNumber>
                <NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D059250" MajorTopicYN="N">Administration, Metronomic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019772" MajorTopicYN="N">Topotecan</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>01</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24569856</ArticleId>
            <ArticleId IdType="doi">10.1007/s10456-014-9422-9</ArticleId>
            <ArticleId IdType="pmc">PMC4540351</ArticleId>
            <ArticleId IdType="mid">NIHMS687512</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2013 Oct;10(10):571-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23999218</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lab Invest. 2012 Jul;92(7):952-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22546866</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Oct 20;26(30):4899-905</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18794539</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2006 Feb 27;94(4):578-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16465194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2012 Jun 1;118(11):2780-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22614656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Jan 1;26(1):76-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18165643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2011 Jan;13(1):40-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21245939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 May;121(1):121-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20339913</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2010 Apr;9(4):996-1006</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20371722</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Aug;7(8):455-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20531380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Apr 26;366(17):1638; author reply 1639-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22533583</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2005 Nov 1;106(9):3058-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15998832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2001 Feb;296(2):537-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11160641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2000 Apr;105(8):R15-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10772661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19168635</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Apr 1;66(7):3386-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16585158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2004 Apr 22;350(17):1713-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15102997</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Jul 15;69(14):5885-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19567673</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):229-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23011602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2008 May 20;98(10):1619-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18443598</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Chromatogr. 2009 Jul;23(7):707-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19277971</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Apr 15;67(8):3560-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17440065</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2009 Aug;8(16):1596-603</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19738426</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Med Genomics. 2009 Apr 24;2:18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19393097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2003 Oct;3(10):721-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">13130303</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1988 Dec 1;48(23):6891-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2846164</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Nov 15;62(22):6698-705</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12438269</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Oct 1;64(19):6845-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15466170</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2001 Jul 20;85(2):242-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11461084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2009 Oct;8(10):2872-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19825805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Nov;124(2):307-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20087649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Sep 15;69(18):7243-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19738068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Mar 20;30(9):921-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22331954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut. 2013 Feb;62(2):259-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22543158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Nov;130(1):133-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21830015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology. 2012;82(4):218-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22508241</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tissue Eng Part C Methods. 2011 Sep;17(9):887-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21486202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Aug 1;24(22):3623-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16877730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Sep 1;17(17):5656-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21788355</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2000 Apr 1;60(7):1878-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10766175</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Jun;4(6):423-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15170445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 26;366(4):374-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22276827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2010 Apr;9(4):985-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20371710</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Oct;129(3):829-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21805309</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>